Clinical Trials Logo

Obese clinical trials

View clinical trials related to Obese.

Filter by:

NCT ID: NCT02180022 Completed - Healthy Clinical Trials

Effects of Onion Peel Extract on Endothelial Function

Start date: April 2013
Phase: Phase 4
Study type: Interventional

Acute or chronic intake of polyphenol-rich foods has been reported to improve endothelial function. Quercetin, found abundantly in onion, is a potent antioxidant flavonoid. This study was designed to investigate whether consumption of onion peel extract (OPE) improves endothelial function in healthy overweight and obese subjects.

NCT ID: NCT02174640 Completed - Healthy Clinical Trials

Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study

COF1
Start date: June 15, 2014
Phase: N/A
Study type: Interventional

The primary objective is to test if acute supplementation with Coffee would improve antioxidant status, following consumption of a pro-oxidative high carbohydrate, high fat meal in over weight/ obese humans. Secondary objective is to determine the ability of coffee to modify postprandial inflammation in overweight/ obese humans.

NCT ID: NCT02167555 Completed - Healthy Clinical Trials

Characterization of Wild Blueberry Polyphenols Bioavailability and Kinetic Profile Over 24-hour Period

WBB
Start date: June 1, 2014
Phase: N/A
Study type: Interventional

Primary objective is to characterize the relative bioavailability and kinetic profile of wild blueberry polyphenols over 24-hours period. Secondary objective is to examine the relationship between bioavailability and kinetic profile of wild blueberry polyphenols on markers of chronic diseases.

NCT ID: NCT02152501 Completed - Overweight Clinical Trials

Exercise and Weight Control

Start date: April 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to research the effects of exercise on calories eaten and expended. The investigator expects to find out whether subjects change their eating and activity behaviors when starting an exercise program.

NCT ID: NCT02136290 Completed - Overweight Clinical Trials

Prepackaged Foods to Promote Weight Loss

CHOICES
Start date: May 2014
Phase: N/A
Study type: Interventional

The primary goal of this clinical trial is to examine whether provision of portion-controlled prepackaged foods in the context of a reduced-energy diet prescription and counseling is associated with a greater degree of weight loss at three months in overweight or obese men and women, compared to usual care or control conditions in which the prescribed reduced-energy diet is to be consumed via self-selected foods. The effect on body weight and recognized indicators of disease risk, diet quality and cardiopulmonary fitness, as well as meal satiety and satisfaction, will also be examined. Participants are 184 overweight or obese men and women in San Diego area who will be randomly assigned to usual care or control conditions.

NCT ID: NCT02135913 Completed - Clinical trials for Vitamin D Deficiency

Roles of Vitamin D and HDL in Obese Children

Start date: January 1, 2016
Phase: N/A
Study type: Interventional

This is a pilot study to determine the association between Vitamin D deficiency in obese children and low high density lipoprotein (HDL) and dysfunctional HDL.

NCT ID: NCT02129608 Completed - Overweight Clinical Trials

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Start date: June 2014
Phase: Phase 3
Study type: Interventional

Currently in the United States about 97 million adults are considered obese, accounting for about 33% of the American adult population (compared to 22.9% in 1988). Obesity, defined as a body mass index of 30.0 or higher, is accountable for 44% of the diabetes, 23% of the ischemic heart disease and between 7% and 41% of certain cancers. The Erchonia® Zerona™ 2.0 Laser (which will be used in this study) has been approved by the FDA (K123237) as a non-invasive dermatological aesthetic treatment which can be used by individuals intending to reduce circumference of hips, waist, and thighs. Lorcaserin is a selective serotonin 2C (5-HT(2C)) receptor agonist. The exact mechanism of action is not known, but lorcaserin is believed to promote satiety and decrease food intake by activating 5-HT(2C) receptors on anorexigenic pro-opiomelanocortin neurons in the hypothalamus. Lorcaserin was approved by the FDA on June 2012 for weight management in people with a BMI of > 27 kg/m2 (overweight) when accompanied by a weigh-related condition such as type 2 diabetes or high blood pressure or in people with a BMI > 30 kg/m2 (obese). The purpose of this pilot study is to obtain preliminary data on: 1) effectiveness of the combination of LLLT and lorcaserin for reducing abdominal subcutaneous fat in overweight/obese individuals; 2) impact of LLLT on inflammatory biomarkers, blood sugar, and cholesterol.

NCT ID: NCT02124512 Completed - Metabolic Syndrome Clinical Trials

Blood Lipopolysaccharide (LPS) Rifaximin Study

Start date: March 2015
Phase: Phase 2
Study type: Interventional

Metabolic syndrome is a condition involving elevated levels of fat in the blood, a tendency towards diabetes, hypertension, and too much fat around the abdomen (an increased waistline). Individuals with metabolic syndrome often have impaired glucose tolerance, which is a condition where blood sugar is normal when fasting (before eating), but is too high after drinking a sugary drink. This is due to an abnormality in the body's sensitivity to insulin (insulin resistance), which is due in part to an inability of the muscle to take up glucose. People with metabolic syndrome have inflammation in their fat tissue and in their blood stream, and the changes in the level of inflammatory chemicals produced by cells in your fat tissues will be studied. One possible source of the inflammation may be the bacteria in the intestine. When individuals eat fatty foods, some of the bacterial products become attached to the fat in their blood and then get directed to fat tissue. The investigators wish to determine whether individuals have an excessive amount of inflammation in their fat tissues, and whether this inflammation comes from the bacteria in their intestines. To determine this, the investigators wish to treat individuals with an antibiotic that reduces the bacteria in their intestines and in their blood, and determine whether this reduces their overall level of inflammation.

NCT ID: NCT02116517 Completed - Hyperlipidemia Clinical Trials

Effects of Green Tea Extract on Obese Women With High Level of LDL

GTE-LDL
Start date: August 2011
Phase: Phase 3
Study type: Interventional

Green tea is one of the most popular beverages in the world. It is believed to have beneficial effect in prevention and treatment of many diseases, one of which is reducing LDL-C. The aim of the study is to examine the effect of supplement containing GTE on obese with high LDL level.

NCT ID: NCT02105428 Completed - Overweight Clinical Trials

Potential Impact of Polycystic Ovarian Syndrome on Protein Modifications and Accumulation

Start date: July 2010
Phase: N/A
Study type: Interventional

A goal of this study is to use a novel methodology to determine whether insulin resistance in women with polycystic ovary syndrome (PCOS) is related to the accumulation of proteins with modifications. This could lead to future research to determine if these modifications interfere with their proper function. Additionally, the investigators will determine how protein quality is affected by exercise training. Aerobic exercise enhances the endogenous oxidant buffering systems which may minimize oxidative damage to proteins. The investigators propose that aerobic exercise minimizes the accrual of modified proteins by increasing the synthesis of new proteins, but also by increasing the degradation and removal of old and damaged proteins. Based on our previous studies the investigators observed that insulin affects plasma protein synthesis and aerobic exercise improves insulin sensitivity not only in muscle but also in liver. The investigators therefore propose that aerobic exercise and related increase in insulin sensitivity (and decline in insulin levels) will reduce accumulation of old and modified skeletal muscle and plasma proteins leading to improved function.